Val-Cit-PAB-Exatecan
Product Specifications
UNSPSC Description
Target Antigen
Drug-Linker Conjugates for ADC; Topoisomerase
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/val-cit-pab-exatecan.html
Solubility
10 mM in DMSO
Smiles
CC(C)[C@H](N)C(N[C@@H](CCCNC(N)=O)C(NC(C=C1)=CC=C1COC(N[C@@H]2C3=C4C(C(N5C4)=CC([C@](O)(C(OC6)=O)CC)=C6C5=O)=NC7=CC(F)=C(C)C(CC2)=C73)=O)=O)=O
Molecular Weight
840.90
References & Citations
[1]Thomas A, et al. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016 Jun;17(6):e254-e262.
Shipping Conditions
Blue Ice
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-153031/Val-Cit-PAB-Exatecan-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-153031/Val-Cit-PAB-Exatecan-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
2227350-99-2
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
ZFYVE19 (Zinc Finger, FYVE Domain Containing 19, FLJ14840, MPFYVE) (MaxLight 550)
ZFYVE19 (Zinc Finger, FYVE Domain Containing 19, FLJ14840, MPFYVE) (MaxLight 550)
RBM28 CRISPRa sgRNA lentivector (set of three targets)(Human)
